Suppr超能文献

利伐沙班单药治疗方案:成功抗凝治疗癌症相关血栓形成的一例病例

Single-drug approach with rivaroxaban: A case of successful anticoagulation against cancer-associated thrombosis.

作者信息

Shioyama Wataru, Oka Toru, Yasui Taku, Fujita Masashi

机构信息

Department of Onco-Cardiology, Osaka International Cancer Institute, Osaka, Japan.

出版信息

J Cardiol Cases. 2019 Jun 28;20(2):39-41. doi: 10.1016/j.jccase.2019.03.005. eCollection 2019 Aug.

Abstract

We report a patient with pulmonary embolism and deep vein thrombosis induced by cancer chemotherapy who received successful anticoagulation using a single-drug approach with rivaroxaban. Cancer-associated thrombosis (CAT) is a leading cause of non-cancer death in patients with cancer, which is induced by cancer itself and/or chemotherapy agents including cisplatin and gemcitabine. By contrast, hemorrhagic state is another feature of advanced cancer. In these opposite conditions of cancer patients, CAT have to be controlled by appropriate anticoagulation. This case shows potential for single-drug approach with rivaroxaban and direct oral anticoagulants being effective and safety strategy against CAT. < Single-drug approach of direct oral anticoagulants (DOACs) against CAT induced by cisplatin and gemcitabine showed satisfactory anticoagulation without heparin and warfarin. CAT has been important issue in oncology field, and single-drug approach of DOACs could be an effective and safety strategy for anticoagulation against CAT.>.

摘要

我们报告了一名因癌症化疗诱发肺栓塞和深静脉血栓形成的患者,该患者使用利伐沙班单药抗凝治疗成功。癌症相关血栓形成(CAT)是癌症患者非癌症死亡的主要原因,它由癌症本身和/或包括顺铂和吉西他滨在内的化疗药物诱发。相比之下,出血状态是晚期癌症的另一个特征。在癌症患者的这些相反情况下,必须通过适当的抗凝来控制CAT。本病例显示了利伐沙班单药治疗以及直接口服抗凝剂作为对抗CAT的有效且安全策略的潜力。<直接口服抗凝剂(DOACs)针对顺铂和吉西他滨诱发的CAT的单药治疗显示,无需肝素和华法林即可实现令人满意的抗凝效果。CAT一直是肿瘤学领域的重要问题,而DOACs的单药治疗可能是对抗CAT的一种有效且安全的抗凝策略。>

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ddf/6698256/eb80eccf21dd/gr1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验